In one paragraphArticle in Cancer research, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from itWhat it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
2 · The registryThe trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
3 · Its place in the literatureWho cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
4 · The recordCorrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
5 · Who and what moneyAuthors and funding
16 authors.
Andrew AukermanDepartment of Epidemiology and Biostatistics, Memorial Sloan Kettering Cancer Center, New York, New York.ORCID 0000-0003-1944-769X Michael L MillerDepartment of Pathology and Cell Biology, Columbia University Irving Medical Center, New York, New York.ORCID 0000-0002-6350-5706 Hanina HibshooshDepartment of Pathology and Cell Biology, Columbia University Irving Medical Center, New York, New York.ORCID 0000-0001-9688-4514 Jasmine A McDonaldDepartment of Epidemiology, Columbia University Irving Medical Center, New York, New York.ORCID 0000-0002-8270-8074 Joy R WinfieldDepartment of Pathology and Cell Biology, Columbia University Irving Medical Center, New York, New York.ORCID 0000-0002-7431-6249 Sai Tun Hein AungDepartment of Pathology and Cell Biology, Columbia University Irving Medical Center, New York, New York.ORCID 0009-0002-3178-1877 Gustavo Martinez-DelgadoDepartment of Pathology and Cell Biology, Columbia University Irving Medical Center, New York, New York.ORCID 0000-0003-4655-3770 Ziv FrankensteinDepartment of Pathology and Cell Biology, Columbia University Irving Medical Center, New York, New York.ORCID 0009-0000-8563-7534 Young-Ho LeeDepartment of Pathology and Cell Biology, Columbia University Irving Medical Center, New York, New York.ORCID 0000-0001-6415-4912 Raul RabadanDepartment of Systems Biology, Columbia University Irving Medical Center, New York, New York.ORCID 0000-0001-7946-9255 Kevin GardnerDepartment of Pathology and Cell Biology, Columbia University Irving Medical Center, New York, New York.ORCID 0000-0001-8018-4353 Funding
X-RAY CRYSTALLOGRAPHYP30CA008748 · NCI · SLOAN-KETTERING INSTITUTE FOR CANCER RES · PI SELWYN M VICKERS · 1985 to 2026
$347.4MTumor Biology and Microenvironment ProgramP30CA013696 · NCI · COLUMBIA UNIV NEW YORK MORNINGSIDE · PI Anil K Rustgi · 1985 to 2026
$115.3MThe Role of CTIP in Lymphocyte Development and LymphomagenesisP01CA174653 · NCI · COLUMBIA UNIVERSITY HEALTH SCIENCES · PI GAUTIER, JEAN · 2014 to 2024
$17.6MProject 3: Role of stromal cell-activated CNOT6L deadenylase in driving AML transformationP01CA285250 · NCI · COLUMBIA UNIVERSITY HEALTH SCIENCES · PI Raul Rabadan · 2024 to 2026
$11.0MTowards a quantitative understanding of tumor evolutionR35CA253126 · NCI · COLUMBIA UNIVERSITY HEALTH SCIENCES · PI Raul Rabadan · 2021 to 2026
$5.6MThe linkage between Race, Kaiso and the tumor microenvironment in breast cancer health disparitiesR01CA253368 · NCI · COLUMBIA UNIVERSITY HEALTH SCIENCES · PI GARDNER, KEVIN L. · 2020 to 2024
$3.3MThe Role of Kaiso as a predictive breast cancer biomarker in Africa and across the African DiasporaR01CA266040 · NCI · COLUMBIA UNIVERSITY HEALTH SCIENCES · PI KEVIN L. GARDNER · 2022 to 2026
$3.1MA transdisciplinary approach for dissecting stem cell states in prostate cancerU01CA261822 · NCI · COLUMBIA UNIVERSITY HEALTH SCIENCES · PI RABADAN, RAUL, SHEN, MICHAEL M. · 2021 to 2025
$3.1MThe role of PHF6 in the control of hematopoietic stem cell aging.R01AG077020 · NIA · COLUMBIA UNIVERSITY HEALTH SCIENCES · PI PALOMERO, TERESA, RABADAN, RAUL · 2021 to 2025
$2.5MThe Tumor Microenvironment and Lymphatic Remodeling in Postpartum Breast CancerR01CA267897 · NCI · COLUMBIA UNIVERSITY HEALTH SCIENCES · PI Jasmine Alise McDonald · 2022 to 2026
$2.4MSCH: Topological Methods for Breast Tissue QuantificationR01CA297843 · NCI · STATE UNIVERSITY NEW YORK STONY BROOK · PI Chao Chen, Prateek Prasanna · 2024 to 2026
$900kDMS/NIGMS 1: Topological Study on Histological Images and Spatial TranscriptomicsR01GM148970 · NIGMS · STATE UNIVERSITY NEW YORK STONY BROOK · PI CHEN, CHAO, JOHNSON, TRAVIS STEELE · 2022 to 2024
$682kNational Institutes of Health (NIH) P01CA174653National Institutes of Health (NIH) P01CA285250National Institutes of Health (NIH) P30CA013696National Institutes of Health (NIH) R01AG077020National Institutes of Health (NIH) R01CA253368National Institutes of Health (NIH) R01CA266040National Institutes of Health (NIH) R01CA267897National Institutes of Health (NIH) R01CA297843National Institutes of Health (NIH) R01GM148970National Institutes of Health (NIH) R01NS1431National Institutes of Health (NIH) R35CA253126National Institutes of Health (NIH) U01CA261822NCI NIH HHS P01 CA174653NCI NIH HHS P01 CA285250NCI NIH HHS P30 CA008748NCI NIH HHS P30 CA013696NCI NIH HHS R01 CA253368NCI NIH HHS R01 CA266040NCI NIH HHS R01 CA267897NCI NIH HHS R01 CA297843NCI NIH HHS R35 CA253126NCI NIH HHS U01 CA261822NIA NIH HHS R01 AG077020NIGMS NIH HHS R01 GM148970
6 · The paper itselfAbstract
Loss of organized structure is a hallmark of malignant transformation in breast cancer. Traditionally, such morphologic features are captured by descriptive histologic assessments, such as grade, that represent reliable diagnostic and prognostic determinants. Nonetheless, the predictive value of these semiquantitative approaches is limited by their subjective nature and the computational restrictions inherent to discrete integer-based scoring systems. In this study, we describe an application of topological measurements and statistical modeling to derive continuous mathematical scores that quantitatively reflect the level of organized structure within human breast cancer tissues. This approach generated quantifiable biomarkers, assessable on a continuous scale, that predicted breast cancer survival. Compared with traditional biomarkers, these topology-based measurements showed higher prognostic accuracy with less variation associated with race and ethnicity. Integration of these biomarkers with gene expression data produced topology-derived gene signatures that predicted therapeutic response and uncovered gene regulatory networks linking metabolism with the breast cancer tumor microenvironment in racially diverse breast cancer cohorts. Overall, this study demonstrates the potential of spatial and topological biomarkers in breast cancer treatment and diagnosis. Application and adaptation of methods that quantify tumor architectural features to develop prognostic and predictive algorithms exemplify the immense future promise of defining linkages among biology, medicine, and mathematics. SIGNIFICANCE: Topological features of breast cancer histology can be quantified on a continuous scale and used to accurately predict breast cancer patient survival and response to therapy.
Indexed as
Biomarkers, TumorBreast NeoplasmsFemaleGene Expression ProfilingGene Expression Regulation, NeoplasticGene Regulatory NetworksHumansPrognosisTumor MicroenvironmentBiomarkers, Tumor
Identifiers
PMID41662167
PMCPMC13055434
What OpenQuestion holds
Textmetadata
LicenceTDM
Read underepoch 390